美国安进的地舒单抗安全性怎么样？

Subcutaneous injection greatly improves patients' medication compliance. At present, many domestic and foreign authoritative guidelines have unanimously affirmed the status of denosumab in breast cancer bone metastasis, and recommended that denosumab should be started after the diagnosis of breast cancer bone metastasis. Let’s learn more about the safety of Amgen’s denosumab in the United States?

Data from a study of Amgen's denosumab: Compared with zoledronic acid, denosumab was better at preventing complications of bone metastases from solid tumors or multiple myeloma.

Compared with zoledronic acid, denosumab can significantly delay the onset of SREs in patients with breast cancer bone metastases, reduce the risk of multiple SREs by 23%, significantly delay the onset of pain by 3.9 months, and reduce the use of powerful opioid analgesics.

Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As a leader in the global biopharmaceutical industry, Guizhou has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry.

The FDA approved denosumab for use in postmenopausal women with osteoporosis who are at high risk for fractures to help reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. Desosumab is also used to reduce the risk of fractures in patients for whom other current treatments are ineffective or intolerable.

On May 27, 2019, denosumab was approved by the National Medical Products Administration for the treatment of giant cell tumor of bone that is unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight >45 kg).

Approved to prevent fractures caused by cancer that has spread to bones, not to prevent or delay the spread of cancer. Desolumab is seen as one of the most important growth drivers for Amgen, the world's largest biotech company.